Buprenorphine Hydrochloride/Samidorphan

盐酸丁丙诺啡/萨米多芬

Report date: 2025/03/05 20:00:52

Base Information

Drug NameBuprenorphine Hydrochloride/Samidorphan
Drug Alias NameALKS 33/Buprenorphine沙氨啡烷/丁丙诺啡Samidorphan and Buprenorphine沙米啡烷+丁丙诺啡Samidorphan●Buprenorphine +[19] 
ClassificationSmall molecules
Mechanisms of ActionMu opioid receptor agonistsKappa opioid receptor antagonistsOpioid receptors antagonists
TargetsMu opioid receptorKappa opioid receptorOpioid receptors
Therapy Area/IndicationsDepressive Disorder, MajorRenal InsufficiencyHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[8] 
CombinationsYes Buprenorphine HydrochlorideSamidorphan
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlkermes Inc
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorRenal InsufficiencyHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A